The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
07:29
Former Energy Minister Sebastian Burduja has a message for those who "say loudly that Romania has no storage": Romanian batteries, not Bulgarian, provide about 650 megawatts to the system, which is almost as much as Reactor 2 at Cernavodă.
07:19
A strong fire broke out on the night from Thursday to Friday at a storage and repair warehouse in Sector 1 of the Capital. A RO-Alert was issued due to the dense smoke.
23:00
A 30-meter luxury yacht, Angiola II, sank in Sardinia a few days after delivery. All 14 people on board were rescued.
22:57
Raúl Castro appeared in Havana to mark 100 years since the birth of his brother, Fidel Castro
22:45
The Swedish Parliament has adopted the reduction of the age of criminal responsibility from 15 to 14 years, with 281 votes in favor. The right-wing government has prioritized combating crime.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
